Analyzing risk factors and developing a stratification system for hepatocellular carcinoma recurrence after interferon-free direct-acting antiviral therapy in chronic hepatitis C patients

Chih-Hsuan Luan,Pin-Shuo Su,Chi-Jen Chu,Chung-Chi Lin,Chien-Wei Su,Jiing-Chyuan Luo,I-Cheng Lee,Chen-Ta Chi,Shou-Dong Lee,Yuan-Jen Wang,Fa-Yauh Lee,Yi-Hsiang Huang,Ming-Chih Hou

DOI: https://doi.org/10.1097/jcma.0000000000001051

2024-01-05

Journal of the Chinese Medical Association

Abstract:Background: The introduction of direct-acting antiviral agents (DAAs) has revolutionized the therapeutic landscape of chronic hepatitis C (CHC), however real-world data on the risk factors of hepatocellular carcinoma (HCC) recurrence following DAA treatment in CHC-HCC patients are limited in Taiwan. We aimed to evaluate the therapeutic efficacy of DAAs in Taiwanese patients with prior HCV-induced HCC and identify the post-treatment risk factors for HCC recurrence. Methods: Between January 2017 and August 2021, 208 CHC-HCC patients underwent DAA treatment at Taipei Veterans General Hospital. Among them, 94 patients met the inclusion criteria (Barcelona clinic liver cancer [BCLC] stage 0/A after treatment with complete radiological response) for analysis. Comprehensive demographic, clinical, and laboratory data were collected before and after DAA treatment. The primary outcome was HCC recurrence post DAA treatment, and independent variables were assessed using multivariate Cox proportional hazards models. Results: The mean age of the enrolled patients was 75.9 ± 8.9 years; 44.7% were male, and 94.7% were Child-Pugh class A. Before DAA treatment, 31.9% experienced HCC recurrence. The median follow-up after DAA treatment was 22.1 months (interquartile range, 8.6-35.9 months). After treatment, 95.7% of the patients achieved a sustained virological response (SVR 12 ), but HCC recurrence occurred in 54.3%. Cumulative HCC recurrence rates after treatment were 31.1% at 1 year, 57.3% at 3 years, and 68.5% at up to 5.69 years. Multivariate analysis revealed that prior HCC recurrence before DAA treatment (HR=3.15, p =0.001), no SVR 12 after treatment (HR=6.829, p =0.016), 12-week post-treatment alpha-fetoprotein (AFP) level > 10 ng/mL (HR=2.34, p =0.036), and BCLC A3 lesions (two or three nodules without any tumor exceeding 3 cm) (HR=2.31, p =0.039) were independent risk factors for HCC recurrence. We further developed a risk stratification system based on these significant independent factors. Conclusion: This investigation underscores the critical influence of factors such as prior HCC recurrence, successful attainment of SVR 12 , post-treatment AFP level, and specific tumor characteristics in determining the risk of HCC recurrence after treatment with DAAs. Our proposed innovative risk stratification system may not only contribute to enhanced personalized care but also holds the potential to optimize treatment outcomes.

medicine, general & internal